Prostate Cancer - Results from #1100

Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy. April 15, 2024

A Systematic Review of the Association between Psychological Resilience and Improved Psychosocial Outcomes in Prostate Cancer Patients. Could Resilience Training Have a Potential Role? April 15, 2024

First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States. April 15, 2024

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. April 15, 2024

Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer. April 12, 2024

A Provider-Facing Decision Support Tool for Prostate Cancer Screening in Primary Care: A Pilot Study. April 12, 2024

Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy. April 12, 2024

Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies. April 12, 2024

Propensity score-matched evaluation of palliative transurethral resection and holmium laser enucleation of the prostate for bladder outlet obstruction in patients with prostate cancer. April 12, 2024

Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort. April 12, 2024

Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool. April 12, 2024

Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany. April 12, 2024

Intraoperative Performance of DaVinci Versus Hugo RAS During Radical Prostatectomy: Focus on Timing, Malfunctioning, Complications, and User Satisfaction in 100 Consecutive Cases (the COMPAR-P Trial). April 11, 2024

ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. April 11, 2024

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors. April 11, 2024

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study. April 11, 2024

Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]. April 11, 2024

Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review. April 11, 2024

Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging. April 10, 2024

Intra-fractional geometric and dose/volume metric variations of magnetic resonance imaging-guided stereotactic radiotherapy of prostate bed after radical prostatectomy. April 10, 2024

Page 56 of 1437